Study Designed to Debunk Risks Raises Questions About Avandia Medicine
A study that was to put to rest the fear that Avandia medicine for Type 2
diabetes is linked with serious risks to users hearts, has instead reinforced
the fear, according to an article in the New York Times (Diabetes Drug
Still Has Heart Risks, Doctors Warn, June 6, 2007).
The Times
article cites recent data posted online in the New England Journal of
Medicine, which only intensified the controversy.
"In short, there is
continued uncertainty about the cardiovascular safety of rosiglitazone," the
Journal editors wrote, referring to the generic name of
Avandia.
Additionally, according to the article, Dr. Rosemary
Johann-Liang, a supervisor in the drug safety office at the Food & Drug
Administration was called to the carpet for approving a warning on
Avandia.
Reportedly, she was ordered to retract her warning and
subsequently lost her power at the office to supervise reviews of the safety of
Avandia.
If you or a loved one has suffered cardiac complications after
ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney.
Get a free case review by filling out the form below.
see also:
FDA Safety Information
FDA Releases New Safety Info on Diabetes Drug Avandia and Side EffectsFDA Updates Public on Safety Information for Avandia and Side Effects
Second Black Box?
FDA: Black Box Warning Label Decision Pending on Avandia Diabetes DrugFDA to Announce Decision on Black Box for Avandia Soon--Lawsuit Info
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001


